/ index (China Daily)
Chinese pharmaceutical companies that want access to the international market are learning how to raise their management standards from the US Food and Drug Administration (FDA), one of the world's strictest regulators.

Positive Phase II Results With Orally Active GnRH Receptor Antagonist In Endometriosis - Neurocrine Biosciences Inc (Medical News Today)
Neurocrine Biosciences,Inc. (Nasdaq: NBIX) today announced positive results of its 'proof ofconcept', safety, efficacy and dose-finding Phase II clinical trial usingits proprietary, orally-active small molecule Gonadotropin-ReleasingHormone (GnRH) receptor antagonist (NBI-56418). The 3-month data comes from a multi-center, randomized, double-blind,placebo-controlled trial involving patients with